Title: County by county estimation of possible deaths averted, infections averted, and cost

savings of overdose prevention centers in the United States from July 2019-June 2025.

Authors: Katie Bailey, PhD, MPA[1], Rohith Palli, MD, PhD[2], Mike Sportiello, MD, PhD[3*],

1. University of California San Diego School of Medicine 9500 Gilman Dr, La Jolla, CA

92093. kkbailey@ucsd.edu

2. University of Washington Department of Biomedical Informatics and Medical

Education, IT Services, and Division of General Internal Medicine. Box 358047. 850

Republican St. Seattle, WA 98195. Rpalli@uw.edu

3. Emory University School of Medicine Department of Medicine. 49 Jesse Hill Dr. SE,

Suite 491, Atlanta, GA 30303. Msporti@emory.edu. ***Corresponding author.**

Abstract

Overdose prevention centers (OPCs), also known as safer injection facilities (SIFs) or supervised consumption sites (SCSs), are a service that allows people to obtain sterile supplies to use their own drugs in a safe environment that is monitored by professionals trained in overdose response and harm reduction. Though still illegal under federal law in the U.S. ("Maintaining Drug-Involved Premises"; "United States v. Safehouse", 2021), many legal or quasi-legal (including some in the U.S.) OPCs have operated since the 1980s. Using CDC overdose death estimates and U.S. Census Bureau population data, we developed a retrospective, scenario-based modeling tool, estimating that 1,329-5,316 deaths could have been averted between July 2019 and June 2025 if 1 out of 100-400 injections had taken place at an OPC. Under these assumptions, 26-105 HIV transmissions and 5,723-22,892 Hepatitis C transmissions could have been averted. Factoring in both discounted lifetime costs to treat those infections as well as the statistical value of deaths averted, $11.9-47.7 billion could have been saved. These data support OPCs as one viable public health intervention to avert deaths and avoid infections. We created a web application that allows users to explore county-level model results and alter model assumptions, including variables like the percent of injections that occur at an OPC.

Introduction

Overdose prevention centers (OPCs), also known as supervised consumption sites (SCSs) or safer injection facilities (SIFs) when designed primarily for people who inject drugs (PWID), offer a monitored setting where people can use pre-obtained drugs with access to sterile supplies, staff trained in overdose response, and referrals to medical, behavioral health, and social services. Many legal or quasi-legal OPCs have operated in multiple countries since the 1980s, including some in the U.S., although they are not clearly authorized under U.S. federal law (Beletsky et al., 2018; "Maintaining Drug-Involved Premises"; "United States v. Safehouse", 2021). Across these settings, overdoses have been managed on-site, with no deaths reported in supervised consumption spaces, in large part due to rapid intervention with naloxone, an opioid overdose reversal agent, and respiratory support such as supplemental oxygen or bag-mask ventilation (Suen et al., 2023).

Research from Canada suggests that OPCs can reduce overdose-related harms, including mortality (Gariepy et al., Sites de consommation supervisee et mortalite par surdose a l'echelle de la population : revue systematique des donnees recentes, 2016-2024./2025). For example, a study of Vancouver's first OPC found a 35% reduction in overdose deaths in the surrounding area compared to smaller declines in the rest of the city (Marshall et al., 2011). In Toronto, spatial analyses estimated that approximately two overdose deaths per 100,000 people were averted annually in areas closest to OPCs (Rammohan et al., 2024). Additional analyses from Ontario found more favorable overdose mortality trends and fewer overdose-related adverse outcomes in areas with greater OPC

presence or capacity (Panagiotoglou & Lim, 2022; T. Robinson et al., 2024; Yeung et al.,

2023), and individual- and population-level studies from Vancouver and Alberta have

similarly suggested that greater OPC engagement is associated with lower overdose

mortality and related harms (Kennedy et al., 2019; Marshall et al., 2021).

Findings, however, have not been uniformly favorable. A controlled interrupted time-

series study from Ontario and a linked cohort analysis from Toronto reported null, mixed, or

limited short-term associations between OPC availability and opioid-related mortality,

acute care use, or other health outcomes at the population level (Day et al., 2026; Tessa

Robinson et al., 2024). These mixed findings likely reflect differences in study design,

follow-up time, geographic scale, service intensity, and the difficulty of isolating OPC

effects amid a rapidly evolving overdose crisis (Gariepy et al., Sites de consommation

supervisee et mortalite par surdose a l'echelle de la population : revue systematique des

donnees recentes, 2016-2024./2025). In the U.S., evidence remains more limited due to

legal restrictions, but includes observational studies of an unsanctioned OPC (Kral et al.,

2020), the first two publicly recognized OPCs in New York City (Harocopos et al., 2022), and

a sanctioned San Francisco-based OPC that has since closed (Suen et al., 2023), with each

reporting high utilization, numerous overdose events managed on-site, and no observed

fatal overdoses within supervised settings.

Modeling studies have also projected meaningful public health and economic

benefits of OPC implementation in specific Canadian and U.S. cities, including estimated

reductions in overdose deaths, infectious disease transmission, ambulance and

emergency department utilization, and health care costs, with resulting favorable cost-

effectiveness estimates (Andresen & Boyd, 2010; Bayoumi & Zaric, 2008; Irwin et al., 2016;

Irwin et al., 2017; Jozaghi et al., 2013). A recent systematic review of economic evaluations

similarly concluded that OPC implementation was consistently associated with favorable

economic outcomes across North American settings (Behrends et al., 2024). Importantly,

however, OPCs may be better aligned with some patterns of drug use and overdose risk

than others. Most evidence on OPC outcomes has focused on opioid-related overdose and

supervised injection drug use, while overdose risk in the U.S. increasingly reflects non-

injection routes of use, including smoking (Ciccarone et al., 2024; Eger et al., 2024;

Karandinos et al., 2024; Kral et al., 2021), as well as growing stimulant involvement (Tanz et

al., 2025). Although some OPCs are adapting to include ventilated spaces for inhalation

(OnPoint, 2025), these services have not traditionally been part of the OPC model. As a

result, the impact of OPCs likely varies depending on local patterns of drug use and the

extent to which site services align with the needs of people at highest risk of overdose.

We build on previous literature to explore the potential impact of OPC

implementation across U.S. communities while accounting for variation in local conditions

and implementation assumptions (Harocopos et al., 2022; Kral et al., 2020). To do so, we

developed a retrospective, scenario-based modeling tool to estimate a range of possible

public health and economic outcomes if OPCs had been implemented across U.S.

counties between July 2019 and June 2025. Specifically, we estimate potential deaths, HIV

and Hepatitis C virus (HCV) infections, and downstream economic burden averted under

varying assumptions about key implementation and utilization parameters, such as

frequency of OPC use among people who inject drugs (PWID). Because the model is

primarily based on assumptions related to supervised injection of opioids, these estimates

are likely most applicable to settings where opioid injection was a major driver of overdose

risk. Rather than estimating a single nationwide causal effect of OPCs, we developed an

interactive web application that enables policymakers, advocates, and other stakeholders

to explore how OPC implementation might have influenced county-level public health

outcomes. We further illustrate the application of this tool through three county-level case

studies, highlighting how estimated outcomes vary across diverse settings and under

different implementation assumptions.

Methods

Provisional 12-month ending drug overdose deaths by county were obtained from

the National Center for Health Statistics for June of each year from 2020 through 2025

(Ahmad et al., 2026); each estimate represents deaths occurring over the preceding 12

months (July–June), yielding non-overlapping annual periods. Population and age data were

downloaded from the U.S. Census Bureau. For this analysis, we assumed 1.5% of adults

were PWID per previous estimates (Bradley et al., 2026; Bradley et al., 2023). For each

PWID, we estimated 508.8 injections per year, or just under 1.5 injections based on prior

estimates (Bradley et al., 2026; Bradley et al., 2023).

Deaths averted

Deaths averted were calculated by assuming the total number of injections stayed constant. Secondly, we assumed that deaths cannot occur after an injection in the OPC, as no reported overdose death has ever occurred in an OPC. The *injections that would occur at an OPC* were calculated by modeling 0.25%, 0.5%, 0.75%, or 1% of injections taking place at the OPC. This led to the following calculation:

$$\frac{Injections\ that\ would\ occur\ at\ OPHC}{PWID * Injections\ per\ person} * Overdose\ deaths = Deaths\ averted$$

With the fraction on the left simplifying to the frequency of total injections in the OPC, multiplied by the number of deaths. If all the injections took place at the OPC, the leftmost fraction would simplify to 1 and all deaths would be averted. If none did, the whole left term would simplify to 0 and no deaths would be averted.

HCV transmissions averted

HCV is a highly transmissible virus in the setting of shared needle use (Pouget et al., 2012), leading to significant morbidity, mortality, and health expenditures (Stepanova & Younossi, 2017). While curative therapy now exists, it is expensive and requires weeks-long adherence, which can be difficult for many PWID as they are disproportionately housing-insecure and have persistent barriers to healthcare engagement (Austin et al., 2022; Kimball et al., 2024). Similar to deaths averted, due to the supply of sterile drug use equipment including needles and cottons, transmission of HCV has never been documented at an OPC. Natural incidence of HCV within PWID varies widely, with study estimates varying from 0.51 to 47 per 100 person years (Gutfraind et al., 2015). For this

132   analysis, we used a lower-end estimate of 10 per 100 person years (Gutfraind et al., 2015),

133   leading to the following equation:

134
$$\frac{Injections\ that\ would\ occur\ at\ OPHC}{PWID * Injections\ per\ person} * HCV\ incidence = HCV\ transmissions\ averted$$

HIV transmissions averted

Though the vast majority of HIV is not transmitted through injection drug use, it is

still a meaningful target of HIV transmission prevention efforts in the U.S. (Centers for

Disease & Prevention, 2024). Others have calculated the incidence of HIV transmission in

groups of PWID, stratifying their use as low, medium, and high risk depending on factors

including how often they share needles with people they know and alternatively with

strangers (Jarlais et al., 2022). Using these incidences, we calculated HIV transmissions

averted with the following equations:

143
$$\frac{Injections\ that\ would\ occur\ at\ OPHC}{PWID * Injections\ per\ person} * HIV\ incidence\ [low\ risk]$$

144
$$= HIV\ transmissions\ averted\ [low\ risk]$$

145
$$\frac{Injections\ that\ would\ occur\ at\ OPHC}{PWID * Injections\ per\ person} * HIV\ incidence\ [medium\ risk]$$

146
$$= HIV\ transmissions\ averted\ [medium\ risk]$$

147
$$\frac{Injections\ that\ would\ occur\ at\ OPHC}{PWID * Injections\ per\ person} * HIV\ incidence\ [high\ risk]$$

148
$$= HIV\ transmissions\ averted\ [high\ risk]$$

Costs averted

Substantial health care dollars are spent treating preventable diseases. Infectious

diseases can be prevented with appropriate education and low-cost materials. Others

have estimated the discounted lifetime cost of an HIV infection to be $448,095 after

adjusting for inflation (Schackman et al., 2015). We calculated the discounted lifetime cost

of an HIV infection with the following equation:

$\$448{,}095 * averted\ HIV\ transmission = Discounted\ cost\ of\ an\ averted\ HIV\ infection$

Similar work has been done to calculate the discounted lifetime cost of HCV,

calculated to $339,968 (after adjusting for inflation) (Liu et al., 2016).

$\$339{,}968 * averted\ HCV\ transmission = Discounted\ cost\ of\ an\ averted\ HCV\ infection$

Finally, we calculated the total economic costs of the lives lost to overdose, using

$7.5 million as the statistical value of life, consistent with conservative estimates used by

U.S. federal agencies (Federal Emergency Management), giving the following equation:

$\$7{,}500{,}000 * Averted\ deaths = Statistical\ costs\ of\ deaths\ averted$

In this work, total costs would include adding up both the discounted costs of HIV

and HCV infections as well as statistical costs of deaths averted:

$Discounted\ infectious\ costs + Statistical\ costs\ of\ daths\ averted = Total\ costs\ averted$

Of note, total costs averted do not include indirect benefits, such as potential

reductions in HIV and HCV transmission outside of the OPC or decreased emergency

service utilization associated with on-site overdose management.

All analysis was performed using R and can be found publicly available here:

https://github.com/sportiellomike/OPC-analysis-code.

 Web application

A free web application ("OPC Data Explorer") was created using the Shiny

infrastructure and written in R (Alboukadel, 2023; Aron et al., 2025; Edzer, 2018; Edzer &

Roger, 2023; Elio, 2025; Garnier et al., 2024; Gregory et al., 2023; Hadley, 2007; Hadley,

Lionel, et al., 2025; Hadley et al., 2019; Hadley, Thomas Lin, et al., 2025; Jeffrey, 2024;

Jeroen, 2025; Kyle & Matt, 2025; Mark et al., 2017; Paolo Di, 2024; Scott et al., 2023; Sergei,

2024; Team, 2025; Teun van den, 2025; Tyson et al., 2025; Winston, 2021; Winston et al.,

2024; Yihui et al., 2024). All code for the data explorer web application is free and open

source and can be found here: https://github.com/sportiellomike/OPC-data-explorer. The

most up to date version of the web application itself can be found here:

https://sportiellomike.shinyapps.io/OPC-data-explorer/. Minimal assistance in coding was

provided by generative artificial intelligence (AI) using claude-3.5-sonnet. All additions

provided by AI were manually checked at the time of coding for both function and syntax.

Generative AI was not utilized to create or manipulate any figure.

Results

Analytic results

Estimates of potential deaths averted are shaped by assumptions regarding the

percentage of injections that occur at an OPC (Table 1). At the low end, assuming 0.25% of

injections occurred at OPCs across U.S. counties, (1 injection out of 400, or one injection

every 287 days [400/(508.8/365)]) per PWID, an estimated 1,329 deaths may have been

averted nationally. At the higher end of 1% of injections occurring at an OPC, 5,316 deaths

may have been averted.

Table 1: Summary table of estimated overdose deaths, infectious diseases, and downstream economic burden

averted under modeled Overdose Prevention Centers implementation across U.S. counties, July 2019-June 2025

Percent of injections occurring at OPC	0.25%	0.5%	0.75%	1%
Deaths averted	1328.91	2657.82	3986.73	5315.64
HCV infections averted	5722.9	11445.98	17168.98	22891.97
HIV-low infections averted	11.45	22.89	34.34	45.78
HIV-medium infections averted	26.33	52.65	78.98	105.30
HIV-high infections averted	32.05	64.10	96.15	128.20
Discounted lifetime cost infections (billions of dollars)	1.96	3.91	5.87	7.83
Cost of life (billions of dollars)	9.97	19.93	29.90	39.87
Total costs (billions of dollars)	11.92	23.85	35.77	47.70

Estimates of HCV infections averted range from 5,723 to just under 22,892 (Table 1),

and dozens of HIV transmissions may have been averted (Table 1). Across all OPC

utilization scenarios, estimated downstream economic burden potentially averted was in

the range of billions to tens of billions of dollars.

Even under more limited implementation scenarios, such as restricting OPCs to the

top 50 counties with the largest estimated populations of PWID (Table 2) or those with the

50 highest rates of overdose deaths per capita (Table 3), projected impacts remained

substantial. A list of these counties can be found in supplementary Tables 1 and 2

respectively.

      Table 2: Estimated overdose deaths, infectious diseases, and downstream economic burden averted under

      modeled Overdose Prevention Centers implementation across the 50 U.S. counties with the greatest number of people

      who inject drugs per capita, July 2019-June 2025

Percent of injections occurring at OPC	0.25%	0.5%	0.75%	1%
Deaths averted	402.49	804.97	1207.46	1609.94
HCV infections averted	1738.93	3477.85	5216.78	6955.71
HIV-low infections averted	3.48	6.96	10.43	13.91
HIV-medium infections averted	8.00	16.00	24.00	32.00
HIV-high infections averted	9.74	19.48	29.21	38.95
Discounted lifetime cost of infections (billions of dollars)	0.59	1.19	1.78	2.38
Cost of life (billions of dollars)	3.02	6.04	9.06	12.07
Total costs (billions of dollars)	0.59	1.19	1.78	2.38

      Table 3: Estimated overdose deaths, infectious diseases, and downstream economic burden averted under

      modeled Overdose Prevention Center implementation across 50 U.S. counties with the highest rates of overdose death

      per capita, July 2019-June 2025

Percent of injections occurring at OPC	0.25%	0.5%	0.75	1%
Deaths averted	52.77	105.54	158.31	211.08
HCV infections averted	83.82	167.64	251.46	335.28
HIV-low infections averted	0.17	0.34	0.50	0.67
HIV-medium infections averted	0.39	0.77	1.16	1.54
HIV-high infections averted	0.47	0.94	1.41	1.88
Discounted lifetime cost of infections (millions of dollars)	0.03	0.06	0.09	0.11

Cost of life (billions of dollars)	0.40	0.79	1.19	1.58
Total costs (billions of dollars)	0.03	0.06	0.09	0.11

Web application

The open-source OPC Data Explorer interactive web application was constructed

for users to investigate estimates in individual counties and create color-coded maps and

tables with additional parameters not reported here (discounted costs broken down

between HIV and HCV, for example) (Figure 1). The most up-to-date version can always be

found at: https://sportiellomike.shinyapps.io/OPC-data-explorer/. Users can dive into the

data and share downloadable figures and analytic tables.

Figure 1: Overdose Prevention Center Data Explorer Web Application

Case studies

To illustrate variations in estimates of how OPC implementation may have impacted

overdose, infectious disease, and economic burden across local contexts, we present

estimates for three counties selected to reflect different epidemiologic and geographic

settings. These examples are intended to demonstrate how the modeling tool may support

local interpretation and planning.

Fulton County, Georgia

Georgia's Fulton County is the most populous in the state and includes most of the

city of Atlanta and its surrounding suburbs. With approximately one million residents,

Fulton County has one of the highest burdens of both overdose mortality and HIV in the

country (Centers for Disease & Prevention, 2024), making it a useful example of a large

urban county where OPC implementation could have substantial impact. The county is one

of the priority jurisdictions in the Ending the HIV Epidemic initiative, with an estimated 2022

HIV incidence of 23.1 per 100,000 people (U. S. Department of Health & Human Services,

2026a). Similar to national trends and the case studies described below, deaths from

inhalation and stimulant use continue to rise in Georgia (Georgia Department of Public

Health, 2025a, 2025b).

Between July 2019 and June 2025, 1,519 Fulton County residents died from

overdose (Ahmad et al., 2026). Under modeled OPC implementation scenarios, we

estimated that 4–16 overdose deaths and 19–75 HCV infections may have been averted,

with minimal impact on HIV transmission (Table 4). The estimated economic value

associated with harms averted ranged from $35–140 million.

Despite being located in a non-Medicaid expansion state with comparatively lower

public health investment, Fulton County has developed a range of services to address

overdose risk (Georgia Overdose Prevention, 2026). However, the substantial burden of

overdose mortality indicates that existing services may not fully meet population need. In

this context, the modeled estimates suggest that even low levels of OPC utilization could

yield measurable reductions in overdose deaths and HCV infections. At the same time, the

modest population-level impact highlights that higher levels of OPC coverage would likely

be necessary to meaningfully reduce overall overdose mortality. Because the model

assumes a uniform prevalence of injection drug use (1.5% of the adult population), these

estimates may be conservative for Southern counties like Fulton, where the population of

people who inject drugs may be larger (Altekruse et al., 2020; Bradley et al., 2026).

Table 4: County-specific estimates of overdose deaths, infectious diseases, and downstream economic burden averted

under modeled Overdose Prevention Center implementation for select counties, July 2019–June 2025[a]

	Fulton County, GA	Monroe County, NY	San Diego County, CA
Real world overdose deaths	1519	1705	4940
Deaths averted	4-16	4-17	12-49
HCV averted	19-75	13-54	58-233
HIV-low averted	0	0	0
HIV-medium averted	0	0	0-1
HIV-high averted	0	0	0-1

Discounted lifetime cost infections (millions of dollars)	6-26	5-20	20-80
Cost of life (millions of dollars)	28-114	32-128	93-371
Total costs (millions of dollars)	35-140	37-146	113-450

257   ᵃData listed as ranges within each cell ranging from estimate at 1/400 injections to 1/100 injections.

258   Monroe County, New York

259   New York's Monroe County is the ninth most populous in the state with

approximately 750,000 residents. The county covers a mix of urban, suburban, and rural

areas with residents of the city of Rochester, the state's fourth-largest city, making up

approximately 27% of the total population. Although Monroe County includes a major

urban center, many overdose deaths occur outside the urban core (New York State

Department of Health, 2026). While overdose death rates have declined more than national

trends in recent years, the local drug supply has shifted, with increasing involvement of

stimulants and xylazine (Granger & Hartman, 2025).

267   During the study period, 1,705 Monroe County residents died from overdose (Table

268   4). Under modeled OPC implementation scenarios, we estimated that between 4-17

269   overdose deaths may have been averted in Monroe County between July 2019 and June

270   2025, and 13-54 HCV infections may have been averted (Table 4). Minimal HIV infections

271   are projected to have been averted by any scenario. Projected downstream economic

272   burden potentially averted ranged from $37-$146 million.

273   New York State has been a national leader in expanding harm reduction services,

including broad access to sterile syringes and the implementation of sanctioned OPCs in

New York City (New York State Department of Health, 2024). In Monroe County, these

efforts are reflected in a relatively robust network of public and non-profit syringe service

programs and naloxone distribution across both fixed and mobile settings (Monroe County

Department of Public Health, 2026; New York State Department of Health, 2024). However,

the distribution of overdose deaths outside the urban core highlights potential gaps in

reach, particularly in suburban and rural areas. In this context, OPC implementation in

Monroe County would likely require careful consideration of geographic need and

accessibility, with potential value in complementing existing services by engaging

populations not consistently reached through current approaches.

San Diego County, California

San Diego County, California, is a large urban county whose proximity to the U.S.–

Mexico border shapes local drug markets and overdose risk. As part of the San Diego–

Imperial Valley High Intensity Drug Trafficking Area (Office of National Drug Control, 2025),

the county has long been situated within a major corridor for drug trafficking while also

facing substantial burden related to overdose and infectious disease. It is also a federal

priority jurisdiction in the Ending the HIV Epidemic initiative, with an estimated HIV

incidence of 14.4 per 100,000 people in 2022 (U. S. Department of Health & Human

Services, 2026b), and more than 55,000 residents with a history of HCV infection (Cheema

et al., 2024).

During the span of this analysis, 4,940 San Diego County residents died from

overdose. Under modeled OPC implementation scenarios, we estimated that between 12-

49 overdose deaths may have been averted in San Diego County between July 2019 and

June 2025. Over the same period, up to 1 HIV infection and 58-233 HCV infections may

have been averted. Projected downstream economic burden potentially averted ranged

from $113-$450 million.

Situated in a state with comparatively supportive harm reduction policies, San

Diego County's harm reduction infrastructure expanded during the study period and

includes multiple syringe services programs offered at fixed sites and via mobile outreach

and widespread naloxone distribution (Bailey et al., 2024; County of San Diego Health &

Human Services Agency, 2024). In this context, the modeled estimates suggest that OPC

implementation could provide additional reductions in overdose deaths beyond those

achieved through existing services and support local HCV prevention goals (Cheema et al.,

2024; U. S. Department of Health & Human Services, 2026b).

Discussion

While it is difficult to estimate the potential use of OPCs among PWID, this study

supplies a framework to assist in estimating their impact on deaths, infections, and

downstream economic burden. Even at very low rates of use, assuming one out of every

400 injections occurs at an OPC, hundreds of deaths and thousands of chronic infections

may have been averted over the period studied. This study also modeled OPC

implementation scenarios in the 50 counties with the most PWID and the 50 counties with

the highest per capita overdose deaths, a potentially more realistic and cost-effective

strategy that we estimate would have had a substantial positive impact on deaths,

infections, and economic burden. We highlighted three counties as brief case studies to

illustrate how this model can be applied in diverse local contexts

Our study has several limitations. Importantly, this analysis does not include

secondary benefits of OPCs, like the potential for participants to voluntarily engage in

treatment programs through referrals from OPC staff (Wood et al., 2007). It also does not

include potential benefits of safer drug use education, such as decreasing the rates of

needle sharing (Kerr et al., 2005). Lastly, this analysis does not include the potential OPC

benefits of connection to secondary social supports, including housing, food, healthcare,

or other programs. This analysis does not include any secondary detriments of OPCs,

though it should be noted that most of those of concern (e.g., increase in overdoses,

increase in new-onset illicit injection drug use) have not been borne out by studies that that

have actually measured these important issues of concern (Kerr et al., 2005; Wood et al.,

2004).

Another important aspect not included in this analysis is the cost to implement and

sustain OPCs, which would require capital and start-up costs, staff salaries, ongoing

supplies, and the costs of maintaining these institutions over time. Another drawback of

this analysis is that its estimations are retrospective rather than projected: we do not make

estimates regarding the impact of future OPCs, just that OPCs could have averted past

adverse outcomes.

Another limitation of this study is the uncertainty in estimating the proportion of

injections that would occur within OPCs if implemented. OPC utilization is likely to vary

across settings based on local infrastructure, service availability, and community context,

as well as characteristics of OPC design and implementation. In addition, the estimated

impact of OPCs on infectious disease transmission may depend on the existing harm

reduction environment; in settings with high coverage of sterile syringe access and other

services, the marginal reductions in HIV and HCV transmission attributable to OPCs may

be smaller. Drug use patterns vary widely across substances, populations, settings, and

interactions with healthcare and law enforcement, even within the same city or

neighborhood, and those who use OPCs may also be motivated to use other harm

reduction resources. A rate of 1 in 400 injections occurring at an OPC would likely arise

from a skewed distribution of use, with some individuals using the OPC frequently and

many using it rarely. As no previous study has estimated the likelihood of OPC uptake per

injection, we presented here a conservative and broad range of 0.25%-1% of injections

occurring at an OPC. Another source of uncertainty is the estimate of injection rates in the

communities without OPCs, which continues to be under debate in the literature and likely

varies across time, neighborhoods, drug supplies, and more. Better objective data is

needed to make these estimates precise.

Relatedly, the feasibility of OPCs has been called into question, especially for more

rural counties where people live less densely: would those who would use the OPC be able

to or desire to travel so far to an OPC? Would there be enough use of the OPC to justify the

cost to set up and run it? As we are not aware of any objective data to help guide the

estimates to these questions, we opted to treat more rural counties identically to the

denser counties, but as we acknowledge, county density likely plays a large role in

implementation decisions. As such, we presented model estimates given OPC

implementation in more realistic scenarios based on population size and overdose burden.

The density critique stems from a traditional but potentially limiting view of OPCs as

standalone structures with dedicated supplies and staff that are independently run.

However, other health care delivery models demonstrate that OPCs need not be fixed

spaces and may be deployed along a spectrum of permanence and independence. In

some communities, especially the densest, it may make sense for OPCs to exist as

standalone, physical structures. However, in less dense communities, OPC-type services

could exist within rural hospital settings, similar to how some rural specialist practices

operate. In even less dense settings, a mobile OPC similar to mobile dentistry and mobile

mammograms may be a solution (Gao et al., 2019; Reuben et al., 2002). Ultimately, our

data reflect not a strict analysis of a pre- and post-intervention, but the large impact minor

reductions in relatively unsafe drug use can have at scale.

As mentioned previously, inhalation overdose deaths continue to rise. This trend

likely reflects multiple factors, including the increasing presence of fentanyl in the drug

supply and shifts in routes of administration away from injection toward inhalation,

facilitated by the distribution of safer smoking supplies (Eger et al., 2024). Similarly, deaths

associated with stimulant use, also often via inhalation, continue to rise (Friedman &

Shover, 2023). Future OPCs should be designed to support those who smoke drugs and

those who use stimulants. Relative to opioid overdoses, stimulant-related overdoses

involve different clinical presentations and do not have a direct pharmacologic reversal

agent such as naloxone. As a result, OPC models that have historically focused on opioid

overdose response may require adaptation to effectively address stimulant and

polysubstance-related harms. We were not able to examine outcomes based on route of

administration (injection, inhalation, other) as this information is not codified in the CDC

overdose death dataset.

In the end, with these caveats in mind, we acknowledge that the total mortality and

morbidity of the ongoing overdose epidemic is difficult to quantify objectively, and that

there is often large degree of confounding in computing the effect of interventions. What

we proposed here is that, based on our modeling approach, OPC implementation could

have contributed to reductions in overdose mortality and morbidity, with effects that

remain meaningful even under conservative assumptions. The exact number of these

estimates could and should be better estimated at the local level and measured

objectively once an intervention is in place.

We invite stakeholders to use our interactive web tool to inform policy discussions

about whether the potential benefits of OPCs outweigh the costs in their communities,

recognizing that these benefits are likely to vary across settings.

Conclusion

Overall, this analysis, facilitated by our interactive, web-based modeling tool,

suggests that OPCs could contribute to reductions in overdose mortality and HCV

transmission, with impacts that vary across local contexts. By enabling stakeholders to

estimate potential effects in their own communities, this work highlights both the potential

value of OPCs and the importance of context-specific implementation. At the same time,

these findings underscore the need for additional empirical research to refine key

assumptions and improve the precision of future estimates.

Acknowledgements

MS was supported by NIH grant T32GM152318 during some of the time of this work. KB is

supported by NIDA grant T32DA023356.

References

References

Ahmad, F. B., Anderson, R. N., Cisewski, J. A., Rossen, L. M., & Sutton, P. (2026). County-level

provisional drug overdose death counts. https://doi.org/10.15620/cdc/20250305009

Alboukadel, K. (2023). *ggpubr: `ggplot2' Based Publication Ready Plots*. In https://CRAN.R-

project.org/package=ggpubr

Altekruse, S. F., Cosgrove, C. M., Altekruse, W. C., Jenkins, R. A., & Blanco, C. (2020).

Socioeconomic risk factors for fatal opioid overdoses in the United States: Findings from

the Mortality Disparities in American Communities Study (MDAC). *PLoS One*, *15*(1),

e0227966. https://doi.org/10.1371/journal.pone.0227966

Andresen, M. A., & Boyd, N. (2010). A cost-benefit and cost-effectiveness analysis of

Vancouver's supervised injection facility. *Int J Drug Policy*, *21*(1), 70–76.

https://doi.org/10.1016/j.drugpo.2009.03.004

Aron, A., Toph, A., Hadley, W., Jonathan, M., & Allaire, J. J. (2025). *rsconnect: Deploy Docs, Apps,*

and APIs to `Posit Connect', `shinyapps.io', and `RPubs'. In https://CRAN.R-

project.org/package=rsconnect

Austin, E. J., Tsui, J. I., Barry, M. P., Tung, E., Glick, S. N., Ninburg, M., & Williams, E. C. (2022).

Health care-seeking experiences for people who inject drugs with hepatitis C: Qualitative

explorations of stigma. *J Subst Abuse Treat*, *137*, 108684.

https://doi.org/10.1016/j.jsat.2021.108684

Bailey, K., Schecter, A., Eger, W. H., Justin Valasek, C. C. J., Strathdee, S. A., Knox, A., Harvey-Vera,

A., Vera, C. F., Goldenberg, S. M., Bazzi, A. R., & Davidson, P. J. (2024). A mixed methods

study to inform fatal overdose prevention in San Diego, California: Perspectives from

people who use drugs. *Int J Drug Policy*, *133*, 104577.

https://doi.org/10.1016/j.drugpo.2024.104577

Bayoumi, A. M., & Zaric, G. S. (2008). The cost-effectiveness of Vancouver's supervised injection

facility. *CMAJ*, *179*(11), 1143–1151. https://doi.org/10.1503/cmaj.080808

Behrends, C. N., Leff, J. A., Lowry, W., Li, J. M., Onuoha, E. N., Fardone, E., Bayoumi, A. M.,

McCollister, K. E., Murphy, S. M., & Schackman, B. R. (2024). Economic Evaluations of

Establishing Opioid Overdose Prevention Centers in 12 North American Cities: A

Systematic Review. *Value Health*, *27*(5), 655–669.

https://doi.org/10.1016/j.jval.2024.02.004

Beletsky, L., Baker, P., Arredondo, J., Emuka, A., Goodman-Meza, D., Medina-Mora, M. E., Werb,

D., Davidson, P., Amon, J. J., Strathdee, S., & Magis-Rodriguez, C. (2018). The global

health and equity imperative for safe consumption facilities. *Lancet*, *392*(10147), 553–

554. https://doi.org/10.1016/S0140-6736(18)31469-7

Bradley, H., Glick, S. N., & Hall, E. W. (2026). Estimated Number of People Who Inject Drugs in

the United States, 2022. *Am J Public Health*, *116*(3), 376–379.

https://doi.org/10.2105/AJPH.2025.308310

Bradley, H., Hall, E. W., Asher, A., Furukawa, N. W., Jones, C. M., Shealey, J., Buchacz, K.,

Handanagic, S., Crepaz, N., & Rosenberg, E. S. (2023). Estimated Number of People Who

Inject Drugs in the United States. *Clin Infect Dis*, *76*(1), 96–102. https://doi.org/10.1093/cid/ciac543

Centers for Disease, C., & Prevention. (2024). Fast Facts: HIV in the United States.

Cheema, J. S., Suckow, S., Ramers, C., Loose, P., Tomada, A., Tweeten, S., Stamos-Buesig, T., Abramovitz, D., Eger, W. H., Strathdee, S. A., & Martin, N. K. (2024). Is San Diego California on Track to Reach HCV Elimination? A Modeling Analysis of Combination Prevention Strategies. *Viruses*, *16*(12). https://doi.org/10.3390/v16121819

Ciccarone, D., Holm, N., Ondocsin, J., Schlosser, A., Fessel, J., Cowan, A., & Mars, S. G. (2024). Innovation and adaptation: The rise of a fentanyl smoking culture in San Francisco. *PLoS One*, *19*(5), e0303403. https://doi.org/10.1371/journal.pone.0303403

County of San Diego Health & Human Services Agency. (2024, 2024/05/21). *Harm Reduction Services*. County of San Diego Health & Human Services Agency. https://www.sandiegocounty.gov/content/sdc/hhsa/programs/phs/hiv_std_hepatitis_branch/Harm_Reduction.html#resources

Day, N., Kaufmann, K., Devoe, D. J. A., Grubac, V., DiMarzo, A., Osmanli, H., Norton, V., Vik, S., Mathew, N., Tanguay, R. L., & Bahji, A. (2026). Healthcare utilization and mortality after overdose prevention site closure: A linked cohort analysis using segmented difference-in-differences time series. *Addiction*. https://doi.org/10.1111/add.70380

Edzer, P. (2018). Simple Features for R: Standardized Support for Spatial Vector Data. *{The R Journal}*, *10*(1), 439–446. https://doi.org/10.32614/RJ-2018-009

Edzer, P., & Roger, B. (2023). *Spatial Data Science: With applications in R*. Chapman and Hall/CRC. https://doi.org/10.1201/9780429459016

Eger, W. H., Abramovitz, D., Bazzi, A. R., Borquez, A., Vera, C. F., Harvey-Vera, A., Friedman, J. R., & Strathdee, S. A. (2024). Changes in injecting versus smoking heroin, fentanyl, and methamphetamine among people who inject drugs in San Diego, California, 2020-2023. *Drug Alcohol Depend*, *259*, 111318. https://doi.org/10.1016/j.drugalcdep.2024.111318

Elio, C. (2025). *ggnewscale: Multiple Fill and Colour Scales in `ggplot2'*. In https://CRAN.R-project.org/package=ggnewscale

Federal Emergency Management, A. Benefit-Cost Analysis.

Friedman, J., & Shover, C. L. (2023). Charting the fourth wave: Geographic, temporal, race/ethnicity and demographic trends in polysubstance fentanyl overdose deaths in the United States, 2010-2021. *Addiction*, *118*(12), 2477–2485. https://doi.org/10.1111/add.16318

Gao, S. S., Yon, M. J. Y., Chen, K. J., Duangthip, D., Lo, E. C. M., & Chu, C. H. (2019). Utilization of a Mobile Dental Vehicle for Oral Healthcare in Rural Areas. *Int J Environ Res Public Health*, *16*(7). https://doi.org/10.3390/ijerph16071234

Gariepy, G., Prowse, R. K. M., Plouffe, R., & Graham, E. (2025). Supervised consumption sites and population-level overdose mortality: a systematic review of recent evidence, 2016-2024. *Health Promot Chronic Dis Prev Can*, *45*(9), 357–366. https://doi.org/10.24095/hpcdp.45.9.02 (Original work published Sites de consommation supervisee et mortalite par surdose a l'echelle de la population : revue systematique des donnees recentes, 2016-2024.)

Garnier, Simon, Ross, Noam, Rudis, Robert, Camargo, Antônio, P., Sciaini, Marco, Scherer, & Cédric. (2024). *viridis(Lite) - Colorblind-Friendly Color Maps for R*. In https://sjmgarnier.github.io/viridis/

Georgia Department of Public Health, D. S. U. (2025a). *Opioid Overdose Surveillance: Preliminary County Report, Georgia, 2023*. https://dph.georgia.gov/epidemiology/drug-surveillance

Georgia Department of Public Health, D. S. U. (2025b). *Stimulant Overdose Surveillance: Preliminary County Report, Georgia, 2023*. https://dph.georgia.gov/epidemiology/drug-surveillance

Georgia Overdose Prevention. (2026). *Georgia Overdose Prevention*. Georgia Overdose Prevention. https://georgiaoverdoseprevention.org/

Granger, N. A., & Hartman, R. L. (2025). *2024 Overdose Deaths in Monroe County*. https://www.monroecounty.gov/files/health/health-action/Overdose%20deaths%20in%20MC%20investigated%20by%20the%20MCOME%202024_color_v2%20(002).pdf

Gregory, R. W., Ben, B., Thomas, L., Arni, M., Bill, V., Genei, R., & Steffen, M. (2023). *gtools: Various R Programming Tools*. In https://CRAN.R-project.org/package=gtools

Gutfraind, A., Boodram, B., Prachand, N., Hailegiorgis, A., Dahari, H., & Major, M. E. (2015). Agent-Based Model Forecasts Aging of the Population of People Who Inject Drugs in Metropolitan Chicago and Changing Prevalence of Hepatitis C Infections. *PLoS One*, *10*(9), e0137993. https://doi.org/10.1371/journal.pone.0137993

Hadley, W. (2007). Reshaping Data with the reshape Package. *Journal of Statistical Software*, *21*(12), 1–20.

Hadley, W., Lionel, H., Thomas Lin, P., Luciani, T. J., Matthieu, D., & Vaudor, L. (2025). *svglite: An `SVG' Graphics Device*. In https://CRAN.R-project.org/package=svglite

Hadley, W., Mara, A., Jennifer, B., Winston, C., Lucy D'Agostino, M., Romain, F., Garrett, G., Alex, H., Lionel, H., Jim, H., Max, K., Thomas Lin, P., Evan, M., Stephan Milton, B., Kirill, M., Jeroen, O., David, R., Dana Paige, S., Vitalie, S.,…Hiroaki, Y. (2019). Welcome to the tidyverse. *Journal of Open Source Software*, *4*(43), 1686. https://doi.org/10.21105/joss.01686

Hadley, W., Thomas Lin, P., & Dana, S. (2025). *scales: Scale Functions for Visualization*. In https://CRAN.R-project.org/package=scales

Harocopos, A., Gibson, B. E., Saha, N., McRae, M. T., See, K., Rivera, S., & Chokshi, D. A. (2022). First 2 Months of Operation at First Publicly Recognized Overdose Prevention Centers in US. *JAMA Netw Open*, *5*(7), e2222149. https://doi.org/10.1001/jamanetworkopen.2022.22149

Irwin, A., Jozaghi, A., Bluthenthal, R. N., & Kral, A. H. (2016). A Cost-Benefit Analysis of a Potential Supervised Injection Facility in San Francisco, California, USA. *Journal of Drug Issues*, *47*(2). https://doi.org/https://doi.org/10.1177/0022042616679829

Irwin, A., Jozaghi, E., Weir, B. W., Allen, S. T., Lindsay, A., & Sherman, S. G. (2017). Mitigating the heroin crisis in Baltimore, MD, USA: a cost-benefit analysis of a hypothetical supervised injection facility. *Harm Reduct J*, *14*(1), 29. https://doi.org/10.1186/s12954-017-0153-2

Jarlais, D. D., Bobashev, G., Feelemyer, J., & McKnight, C. (2022). Modeling HIV transmission among persons who inject drugs (PWID) at the "End of the HIV Epidemic" and during the COVID-19 pandemic. *Drug Alcohol Depend*, *238*, 109573. https://doi.org/10.1016/j.drugalcdep.2022.109573

Jeffrey, B. A. (2024). *ggthemes: Extra Themes, Scales and Geoms for `ggplot2`*. In https://CRAN.R-project.org/package=ggthemes

Jeroen, O. (2025). *writexl: Export Data Frames to Excel `xlsx` Format*. In https://CRAN.R-project.org/package=writexl

Jozaghi, E., Reid, A. A., & Andresen, M. A. (2013). A cost-benefit/cost-effectiveness analysis of proposed supervised injection facilities in Montreal, Canada. *Subst Abuse Treat Prev Policy*, *8*, 25. https://doi.org/10.1186/1747-597X-8-25

Karandinos, G., Unick, J., Ondocsin, J., Holm, N., Mars, S., Montero, F., Rosenblum, D., & Ciccarone, D. (2024). Decrease in injection and rise in smoking and snorting of heroin and synthetic opioids, 2000-2021. *Drug Alcohol Depend*, *263*, 111419. https://doi.org/10.1016/j.drugalcdep.2024.111419

Kennedy, M. C., Hayashi, K., Milloy, M. J., Wood, E., & Kerr, T. (2019). Supervised injection facility use and all-cause mortality among people who inject drugs in Vancouver, Canada: A cohort study. *PLoS medicine*, *16*(11), e1002964. https://doi.org/10.1371/journal.pmed.1002964

Kerr, T., Tyndall, M., Li, K., Montaner, J., & Wood, E. (2005). Safer injection facility use and syringe sharing in injection drug users. *Lancet*, *366*(9482), 316–318. https://doi.org/10.1016/S0140-6736(05)66475-6

Kimball, S., Reynoso, M., McKnight, C., & Des Jarlais, D. (2024). Hepatitis C treatment outcomes among people who inject drugs experiencing unstable versus stable housing: Systematic review and meta-analysis. *PLoS One*, *19*(4), e0302471. https://doi.org/10.1371/journal.pone.0302471

Kral, A. H., Lambdin, B. H., Browne, E. N., Wenger, L. D., Bluthenthal, R. N., Zibbell, J. E., & Davidson, P. J. (2021). Transition from injecting opioids to smoking fentanyl in San Francisco, California. *Drug Alcohol Depend*, *227*, 109003. https://doi.org/10.1016/j.drugalcdep.2021.109003

Kral, A. H., Lambdin, B. H., Wenger, L. D., & Davidson, P. J. (2020). Evaluation of an Unsanctioned Safe Consumption Site in the United States. *N Engl J Med*, *383*(6), 589–590. https://doi.org/10.1056/NEJMc2015435

Kyle, W., & Matt, H. (2025). *tidycensus: Load US Census Boundary and Attribute Data as `tidyverse` and `sf`-Ready Data Frames*. In https://CRAN.R-project.org/package=tidycensus

Liu, S., Barnett, P. G., Holodniy, M., Lo, J., Joyce, V. R., Gidwani, R., Asch, S. M., Owens, D. K., & Goldhaber-Fiebert, J. D. (2016). Cost-Effectiveness of Treatments for Genotype 1 Hepatitis C Virus Infection in non-VA and VA Populations. *MDM Policy Pract*, *1*(1). https://doi.org/10.1177/2381468316671946

Maintaining Drug-Involved Premises, 21 U.S. Government Publishing Office § 856. https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section856

Mark, P., Bob, R., Robin, L., & Maëlle, S. (2017). osmdata. *Journal of Open Source Software*,
2(14), 305. https://doi.org/10.21105/joss.00305

Marshall, B. D. L., Milloy, M. J., Wood, E., Montaner, J. S. G., & Kerr, T. (2011). Reduction in
overdose mortality after the opening of North America's first medically supervised safer
injecting facility: a retrospective population-based study. *Lancet*, *377*(9775).
https://doi.org/10.1016/S0140-6736(10)62353-7

Marshall, T., Abba-Aji, A., Tanguay, R., & Greenshaw, A. J. (2021). The Impact of Supervised
Consumption Services on Fentanyl-related Deaths: Lessons Learned from Alberta's
Provincial Data. *Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie*,
66(12), 1096–1098. https://doi.org/10.1177/0706743721999571

Monroe County Department of Public Health. (2026). *NaloxBox Locations Map*. Monroe County,
New York. https://www.monroecounty.gov/narcan

New York State Department of Health. (2026). Opioid Data Dashboard: County Reports.

New York State Department of Health, O. o. D. U. H. (2024, 2024/07). *Syringe Access & Drug*
User Health Hub Programs. New York State Department of Health.
https://www.health.state.ny.us/diseases/aids/consumers/prevention/syringe_access.ht
m

Office of National Drug Control, P. (2025). San Diego - Imperial Valley High Intensity Drug
Trafficking Area (HIDTA).

OnPoint, N. Y. C. (2025). Overdose Prevention Centers.

Panagiotoglou, D., & Lim, J. (2022). Using synthetic controls to estimate the population-level
effects of Ontario's recently implemented overdose prevention sites and consumption
and treatment services. *The International Journal on Drug Policy*, *110*, 103881.
https://doi.org/10.1016/j.drugpo.2022.103881

Paolo Di, L. (2024). *usmap: US Maps Including Alaska and Hawaii*. In https://CRAN.R-
project.org/package=usmap

Pouget, E. R., Hagan, H., & Des Jarlais, D. C. (2012). Meta-analysis of hepatitis C seroconversion
in relation to shared syringes and drug preparation equipment. *Addiction*, *107*(6), 1057–
1065. https://doi.org/10.1111/j.1360-0443.2011.03765.x

Rammohan, I., Gaines, T., Scheim, A., Bayoumi, A., & Werb, D. (2024). Overdose mortality
incidence and supervised consumption services in Toronto, Canada: an ecological study
and spatial analysis. *The Lancet Public Health*, *9*(2), e79–e87.
https://doi.org/10.1016/S2468-2667(23)00300-6

Reuben, D. B., Bassett, L. W., Hirsch, S. H., Jackson, C. A., & Bastani, R. (2002). A randomized
clinical trial to assess the benefit of offering on-site mobile mammography in addition to
health education for older women. *AJR Am J Roentgenol*, *179*(6), 1509–1514.
https://doi.org/10.2214/ajr.179.6.1791509

Robinson, T., Farrokhyar, F., & Fischer, B. (2024). The associations of supervised consumption
services with the rates of opioid-related mortality and morbidity outcomes at the public
health unit level in Ontario (Canada): A controlled interrupted time-series analysis. *Drug*
and Alcohol Review, *43*(7), 1880–1891. https://doi.org/10.1111/dar.13921

Robinson, T., Farrokhyar, F., & Fischer, B. (2024). The associations of supervised consumption services with the rates of opioid-related mortality and morbidity outcomes at the public health unit level in Ontario (Canada): A controlled interrupted time-series analysis. *Drug Alcohol Rev*, *43*(7), 1880–1891. https://doi.org/10.1111/dar.13921

Schackman, B. R., Fleishman, J. A., Su, A. E., Berkowitz, B. K., Moore, R. D., Walensky, R. P., Becker, J. E., Voss, C., Paltiel, A. D., Weinstein, M. C., Freedberg, K. A., Gebo, K. A., & Losina, E. (2015). The lifetime medical cost savings from preventing HIV in the United States. *Med Care*, *53*(4), 293–301. https://doi.org/10.1097/MLR.0000000000000308

Scott, C., Andy, T., & Michael, M. (2023). *geojsonio: Convert Data from and to `GeoJSON' or `TopoJSON'*. In https://CRAN.R-project.org/package=geojsonio

Sergei, I. (2024). *tictoc: Functions for Timing R Scripts, as Well as Implementations of ``Stack'' and ``StackList'' Structures*. In https://CRAN.R-project.org/package=tictoc

Stepanova, M., & Younossi, Z. M. (2017). Economic Burden of Hepatitis C Infection. *Clin Liver Dis*, *21*(3), 579–594. https://doi.org/10.1016/j.cld.2017.03.012

Suen, L. W., Wenger, L. D., Morris, T., Majano, V., Davidson, P. J., Browne, E. N., Ray, B., Megerian, C. E., Lambdin, B. H., & Kral, A. H. (2023). Evaluating oxygen monitoring and administration during overdose responses at a sanctioned overdose prevention site in San Francisco, California: A mixed-methods study. *Int J Drug Policy*, *121*, 104165. https://doi.org/10.1016/j.drugpo.2023.104165

Tanz, L. J., Miller, K. D., Dinwiddie, A. T., Gladden, R. M., Asher, A., Baldwin, G., Nesbit, B., & O'Donnell, J. (2025). Drug Overdose Deaths Involving Stimulants - United States, January 2018-June 2024. *MMWR Morb Mortal Wkly Rep*, *74*(32), 491–499. https://doi.org/10.15585/mmwr.mm7432a1

Team, R. C. (2025). *R: A Language and Environment for Statistical Computing*. In R Foundation for Statistical Computing. https://www.R-project.org/

Teun van den, B. (2025). *legendry: Extended Legends and Axes for `ggplot2'*. In https://CRAN.R-project.org/package=legendry

Tyson, B., Matt, D., Arun, S., Jan, G., Michael, C., Toby, H., Benjamin, S., & Ivan, K. (2025). *data.table: Extension of `data.frame'*. In https://CRAN.R-project.org/package=data.table

U. S. Department of Health & Human Services. (2026a, 2022). *Fulton County HIV Data America's HIV Epidemic Analysis Dashboard (AHEAD)*. U.S. Department of Health and Human Services, Office of Infectious Disease and HIV/AIDS Policy. https://ahead.hiv.gov/georgia/fulton_county/

U. S. Department of Health & Human Services. (2026b). *San Diego HIV Data America's HIV Epidemic Analysis Dashboard (AHEAD)*. America's HIV Epidemic Analysis Dashboard (AHEAD). https://ahead.hiv.gov/california/san_diego_county

United States v. Safehouse, 985 225–272 (2021). https://law.justia.com/cases/federal/appellate-courts/ca3/19-3835/19-3835-2021-01-12.html

Winston, C. (2021). *shinythemes: Themes for Shiny*. In https://CRAN.R-project.org/package=shinythemes

Winston, C., Joe, C., Allaire, J. J., Carson, S., Barret, S., Yihui, X., Jeff, A., Jonathan, M., Alan, D., &
Barbara, B. (2024). *shiny: Web Application Framework for R*. In https://CRAN.R-
project.org/package=shiny
Wood, E., Kerr, T., Small, W., Li, K., Marsh, D. C., Montaner, J. S., & Tyndall, M. W. (2004).
Changes in public order after the opening of a medically supervised safer injecting
facility for illicit injection drug users. *CMAJ*, *171*(7), 731–734.
https://doi.org/10.1503/cmaj.1040774
Wood, E., Tyndall, M. W., Zhang, R., Montaner, J. S., & Kerr, T. (2007). Rate of detoxification
service use and its impact among a cohort of supervised injecting facility users.
Addiction, *102*(6), 916–919. https://doi.org/10.1111/j.1360-0443.2007.01818.x
Yeung, M. E. M., Lee, C. H., Hartmann, R., & Lang, E. (2023). Opioid-related emergency
department visits and deaths after a harm-reduction intervention: a retrospective
observational cohort time series analysis. *CMAJ Open*, *11*(3), E537–E545.
https://doi.org/10.9778/cmajo.20220104
Yihui, X., Joe, C., & Xianying, T. (2024). *DT: A Wrapper of the JavaScript Library `DataTables'*. In
https://CRAN.R-project.org/package=DT
672

Counties with highest number of PWID
California-Los Angeles County
Illinois-Cook County
Texas-Harris County
Arizona-Maricopa County
California-San Diego County
California-Orange County
Florida-Miami-Dade County
New York-Kings County
Texas-Dallas County
New York-Queens County
California-Riverside County
Washington-King County
Nevada-Clark County
California-San Bernardino County
Texas-Tarrant County
Florida-Broward County
Texas-Bexar County
California-Santa Clara County
New York-New York County

Michigan-Wayne County
California-Alameda County
Massachusetts-Middlesex County
Pennsylvania-Philadelphia County
Florida-Palm Beach County
California-Sacramento County
New York-Suffolk County
Florida-Hillsborough County
Florida-Orange County
New York-Nassau County
New York-Bronx County
Texas-Travis County
Ohio-Franklin County
Michigan-Oakland County
Pennsylvania-Allegheny County
Minnesota-Hennepin County
Ohio-Cuyahoga County
California-Contra Costa County
North Carolina-Wake County
Virginia-Fairfax County

Utah-Salt Lake County
North Carolina-Mecklenburg County
Georgia-Fulton County
Arizona-Pima County
Texas-Collin County
Maryland-Montgomery County
Florida-Pinellas County
Hawaii-Honolulu County
New York-Westchester County
Florida-Duval County
Missouri-St. Louis County

674   *Supplementary table 1: Counties with highest number of PWID*

Counties with highest deaths per capita
Texas-Borden County
New Mexico-Rio Arriba County
Kentucky-Lee County
Nebraska-Logan County
Texas-Kent County
New Mexico-Taos County

Alaska-Lake and Peninsula County
California-Lake County
Kentucky-Powell County
West Virginia-Logan County
Maryland-Baltimore (city) County
West Virginia-Cabell County
Kansas-Greeley County
Kentucky-Estill County
West Virginia-Lincoln County
Kentucky-Knott County
Kentucky-Breathitt County
West Virginia-Mercer County
California-Del Norte County
Kentucky-Boyd County
Arizona-La Paz County
West Virginia-Mingo County
Texas-Karnes County
Tennessee-Roane County
Texas-Irion County
Louisiana-Washington County

Washington-Okanogan County
Alaska-Anchorage County
Kentucky-Clay County
Tennessee-Morgan County
Tennessee-DeKalb County
Washington-Grays Harbor County
West Virginia-McDowell County
Alabama-Walker County
Virginia-Buchanan County
Kentucky-Rockcastle County
Missouri-St. Louis (city) County
Texas-Dickens County
North Dakota-Golden Valley County
California-Butte County
California-Alpine County
Tennessee-Cocke County
New Mexico-Santa Fe County
Nebraska-Garden County
Washington-Spokane County
Kentucky-Harlan County

Colorado-Cheyenne County
Pennsylvania-Philadelphia County
Tennessee-Campbell County
Utah-Piute County

676 *Supplementary table 2: Counties with highest deaths per capita*

OPC Data Explorer

Select State:

Georgia

Select County:

Fulton County

Select Year:

2025

Select what percent of injections happent at OPC:

Select Column for Plot Color:

cumulativelivessaved

Select Transformation:

log2(1+value)

Legend Label:

Cumulative deaths averted

Legend Text Size:

Legend Minimum:

Legend Maximum:

Plots   Local Results   National Results   Data

Plots for subset of data selected on the left